



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Non coding RNAs in vascular disease - from basic science to clinical applications

Citation for published version:

Fiedler, J, Baker, AH, Dimmeler, S, Heymans, S, Mayr, M & Thum, T 2018, 'Non coding RNAs in vascular disease - from basic science to clinical applications: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology' *Cardiovascular Research*. DOI: 10.1093/cvr/cvy121

Digital Object Identifier (DOI):

[10.1093/cvr/cvy121](https://doi.org/10.1093/cvr/cvy121)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Cardiovascular Research

Publisher Rights Statement:

this is the authors accepted manuscript as accepted by Cardiovascular Research on 16 May 2018

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Cardiovascular Research

Update on non-coding RNAs in vascular disease - from basic discoveries to clinical applications --Manuscript Draft--

Manuscript Number:	CVR-2018-115R2
Full Title:	Update on non-coding RNAs in vascular disease - from basic discoveries to clinical applications
Short Title:	Non-coding RNAs in the vasculature
Article Type:	Invited Spotlight Review
Keywords:	non-coding RNA vascular disease biomarker
Corresponding Author:	Thomas Thum, MD, PhD Hannover Medical School Hannover, GERMANY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Hannover Medical School
Corresponding Author's Secondary Institution:	
First Author:	Jan Fiedler
First Author Secondary Information:	
Order of Authors:	Jan Fiedler Andrew Baker Stefanie Dimmeler Stephane Heymans Manuel Mayr Thomas Thum, MD, PhD
Order of Authors Secondary Information:	
Abstract:	Non-coding RNAs are increasingly recognized not only as regulators of various biological functions but also as targets for a new generation of RNA therapeutics and biomarkers. We hereby review recent insights relating to non-coding RNAs including microRNAs (e.g. miR-126, miR-146a), long non-coding RNAs (e.g. MIR503HG, GATA6-AS, SMILR) and circular RNAs (e.g. cZNF292) and their role in vascular diseases. This includes identification and therapeutic use of hypoxia-regulated non-coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth muscle cell signalling, age-related non-coding RNAs and non-coding RNAs involved in the regulation of mitochondrial biology and metabolic control. Finally, we discuss non-coding RNA species with biomarker potential.

CVR-2018-115

Abstract

Non-coding RNAs are increasingly recognized not only as regulators of various biological functions but also as targets for a new generation of RNA therapeutics and biomarkers. [We hereby review recent insights](#) relating to non-coding RNAs including microRNAs (e.g. [miR-126](#), [miR-146a](#)), long non-coding RNAs (e.g. [MIR503HG](#), [GATA6-AS](#), [SMILR](#)) and circular RNAs (e.g. [cZNF292](#)) and their role in vascular diseases. This includes identification and therapeutic use of hypoxia-regulated non-coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth muscle cell signalling, age-related non-coding RNAs and non-coding RNAs involved in the regulation of mitochondrial biology and metabolic control. [Finally, we discuss](#) non-coding RNA species with biomarker potential.



**Medizinische Hochschule
Hannover**

MHH, Molekulare und Translationale Therapiestrategien (IMTTS)

Institute of Molecular and Translational
Therapeutic Strategies (IMTTS), OE8886
Prof. Dr. med. Thomas Thum, MD, PhD
Telefon: +49-511 532-5272
Email: Thum.Thomas@mh-hannover.de

Professor of Cardiology,
Imperial College London, UK

Carl-Neuberg-Straße 1
30625 Hannover
Germany
www.mh-hannover.de

Editor-in-Chief

Tomasz J. Guzik

Cardiovascular Research

19. April 2018

Manuscript CVR-2018-115

“Update on non-coding RNAs in vascular disease – from basic discoveries to clinical applications”

Dear Dr. Guzik,

We would like to thank the Editor and Reviewers for their careful consideration and evaluation of our review article. We addressed suggestions in a point-by-point response, revised the text and hope that our article is now acceptable for publication in CVR. Changes to the manuscript are highlighted in blue text colour.

Best wishes,

Thomas Thum & Jan Fiedler

Reviewers' comments:

Reviewer #1: The authors did a very good job addressing the many comments

Reply:

We appreciate the support of our review article and thank for previous valuable comments.

Reviewer #2: This version is sufficiently improved to be publishable but I am disappointed that they have only done the bare minimum required. The language is still sub-optimal and I am not convinced that many of the authors have proof-read it.

Reply:

We again proof-read the manuscript and have corrected wording at some points.

Reviewer #3: The authors have largely addressed most of my points apart from, in my opinion extending abstract. I think, that making it more direct and detailed will increase citability of this paper which will be good for both authors and journal. I would suggest including maybe examples of non-coding RNAs discussed or key mechanisms they regulate. Apart from that I think this is a very interesting apaper that should be published.

Reply:

We are thankful for support of our review article and followed up the suggestion to include distinct non-coding RNAs within the abstract. Mentioned non-coding RNAs now include miR-126, miR-146a, MIR503HG, GATA6-AS, SMILR and cZNF292.

Update on non-coding RNAs in vascular disease – from basic discoveries to clinical applications

Jan Fiedler¹, Andrew H Baker², Stefanie Dimmeler³, Stephane Heymans^{4,5,6}, Manuel Mayr⁷ and Thomas Thum^{1,8,9}

¹Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany

²Centre for Cardiovascular Sciences, Queen's Medical Research Institute, Edinburgh, UK

³Institute for Cardiovascular Regeneration, Goethe University, Frankfurt am Main, Germany

⁴Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands

⁵Netherlands Heart Institute, Utrecht, The Netherlands

⁶Department of Cardiovascular Sciences, Leuven University, Belgium

⁷King's British Heart Foundation Centre, King's College London, United Kingdom

⁸National Heart and Lung Institute, Imperial College London, London, UK

⁹Excellence Cluster REBIRTH, Hannover Medical School, Hannover, Germany

Running title: Non-coding RNAs in the vasculature

Address for correspondence:

Thomas Thum, MD, PhD, FESC, FAHA, FHFA

Institute of Molecular and Translational Therapeutic Strategies (IMTTS),

Hannover Medical School

Carl-Neuberg-Str. 1

30625 Hannover

Phone: +49 511/532-5272

Fax: +49 511/532-5274

Email: thum.thomas@mh-hannover.de

Abstract

Non-coding RNAs are increasingly recognized not only as regulators of various biological functions but also as targets for a new generation of RNA therapeutics and biomarkers. [We hereby review recent insights](#) relating to non-coding RNAs including microRNAs (e.g. [miR-126](#), [miR-146a](#)), long non-coding RNAs (e.g. [MIR503HG](#), [GATA6-AS](#), [SMILR](#)) and circular RNAs (e.g. [cZNF292](#)) and their role in vascular diseases. This includes identification and therapeutic use of hypoxia-regulated non-coding RNAs and endogenous non-coding RNAs that regulate intrinsic smooth muscle cell signalling, age-related non-coding RNAs and non-coding RNAs involved in the regulation of mitochondrial biology and metabolic control. [Finally, we discuss](#) non-coding RNA species with biomarker potential.

Introduction

Manifestations of vascular diseases are the leading causes of morbidity and mortality¹. Endothelial dysfunction is a key initiator of vascular disease. Proliferation, migration and the phenotype switch of smooth muscle cells are further hallmarks of vascular disease. Inflammatory cells aggravate vascular disease by release of secreted growth factors and cytokines, as well as cell/cell interactions that perpetuate the response to injury. Relatively recently, non-coding RNA has been discovered as new regulators of vascular function and angiogenesis. Non-coding RNAs include microRNAs (miRs, miRNAs, short non-coding RNAs of about 20nt length), long non-coding RNAs (lncRNAs) (length of >200 nt) as well as circular RNAs, a specific subtype of lncRNAs that form circular structures² through back-splicing events. Here, we focus on recent new insights how non-coding RNAs constitute regulatory therapeutic targets and biomarkers in vascular disease, with a special focus on cardiac disease-associated factors (e.g. hypoxia, ageing, smooth muscle cell biology and metabolism).

Hypoxia-regulated non-coding RNAs

Hypoxia is a key trigger for angiogenic events and has a substantial impact on the non-coding transcriptome. Oxygen depletion alters endothelial expression of a wide range of lncRNAs, as indicated by next-generation RNA sequencing and microarray approaches in endothelial cells subjected to hypoxia³. Validation experiments confirmed strong hypoxia-dependent activation of 2 intergenic lncRNAs (LINC00323 and MIR503HG). Silencing of these lncRNA transcripts led to angiogenic defects, including repression of growth factor signaling and/or the key endothelial transcription factor GATA2. Endothelial loss of these hypoxia-driven lncRNAs impaired cell-cycle control and inhibited capillary formation. The potential clinical importance of identified

endothelial lncRNAs to vascular structural integrity was demonstrated in an *ex vivo* model of human induced pluripotent stem cell-based engineered heart tissue (EHT) showing that pharmacological inhibition of these lncRNAs impaired vascular structure appearance. Interestingly, research in the non-coding RNA field discovered the well-known endothelial (and protein-coding RNA) transcription factor GATA2 as a common target for many non-coding RNAs ⁴. GATA2 orchestrates the expression of many endothelial-specific genes, illustrating its crucial importance for endothelial cell function ⁵. In addition to being regulated through the actions of endothelial lncRNAs LINC00323 and MIR503HG, GATA2 was recently identified to be also a master switch for several key microRNAs. Using profiling approaches, the GATA2-dependent miR transcriptome was identified ⁶. Indeed, global miRNAome-screening identified several GATA2-regulated miRNAs, including miR-126 and miR-221. Specifically, proangiogenic miR-126 was regulated by GATA2 transcriptionally and targeted antiangiogenic SPRED1 and FOXO3a contributing to GATA2-mediated formation of normal vascular structures, whereas GATA2 deficiency led to vascular abnormalities. In contrast to GATA2 deficiency, supplementation with miR-126 normalized vascular function and expression profiles of cytokines contributing to proangiogenic paracrine effects. GATA2 silencing resulted in endothelial DNA hypomethylation leading to induced expression of antiangiogenic miR-221 by GATA2-dependent demethylation of a putative CpG island in the miR-221 promoter. Mechanistically, a reverted GATA2 phenotype by endogenous suppression of miR-221 was mediated through direct proangiogenic miR-221 target genes ICAM1 and ETS1. Of therapeutic importance was the finding that in a mouse model of carotid injury with endothelial-specific repressed GATA2, systemic supplementation of miR-126-coupled nanoparticles enhanced miR-126 availability in the carotid artery. MiR-

126 improved reendothelialization of injured carotid arteries *in vivo* thus proving a therapeutic strategy for treatment of GATA2-deficient vascular diseases.

An additional screen for hypoxia-regulated lncRNAs revealed that the long non-coding antisense transcript of GATA6 (GATA6-AS) is induced by hypoxia in endothelial cells as well ⁷. Silencing of GATA6-AS in endothelial cells *in vitro* diminished TGF- β 2-induced endothelial-mesenchymal transition. Transplantation of GATA6-AS modulated human umbilical vein endothelial cells (HUVECs) via application of an antisense oligonucleotide (GapmeR) promoted the formation of human blood vessels in immune deficient mice. Mechanistically, GATA6-AS interacted with the known deaminase LOXL2, which can remove activating H3K4me3 chromatin marks, and controlled a set of angiogenesis-related genes that are inversely regulated by LOXL2 and GATA6-AS silencing. Specifically, GATA6-AS silencing reduces H3K4me3 methylation of two of these genes, periostin and cyclooxygenase-2, suggesting that GATA6-AS acts as negative regulator of nuclear LOXL2 function. Interestingly, - at least in endothelial cells *in vitro* - the levels of secreted LoxL2, which are known to regulate collagen cross-linking and are implicated in cardiac fibrosis ⁸, were not affected.

Non-coding RNAs are also molecular targets in therapeutic revascularization. It was recently demonstrated that endothelial cells can be derived via both directed differentiation and haematopoietic origin ⁹. Expression of the lncRNA SENCER, a lncRNA [already](#) known to be expressed in vascular SMCs, ¹⁰ was upregulated upon differentiation to endothelial cells, and manipulation of SENCER during differentiation affected endothelial cell appearance. Interestingly, SENCER modulation modified the angiogenic phenotype of endothelial cells, suggesting that lncRNAs have important regulatory functions for vascular cell types. Such studies are consistent with others in

the field, assessing different lncRNA in endothelial cells ¹¹⁻¹³. Circulating levels of SENCR are also an independent predictor of diastolic function and remodeling in patients with type 2 diabetes ¹⁴.

Apart from linear lncRNAs, circular forms of RNA species exist and are differentially regulated in the context of cardiovascular diseases ^{2, 15}. CircRNAs lack polyadenylation, are resistant to RNase R digestion and localized to the cytoplasm. Boeckel et al explored the expression and function of circular RNAs in endothelial cells ¹⁶. Using a modified computational analysis pipeline ¹⁷, RNA sequencing data of ribo-minus RNA from HUVECs cultured under normoxic or hypoxic conditions was analysed. cZNF292, cAFF1, and cDENND4C were shown to be up-regulated by hypoxia. Silencing of cZNF292 inhibited cZNF292 expression and reduced tube formation and spheroid sprouting of endothelial cells *in vitro*. Since circRNAs were previously suggested to act as microRNA sponges ¹⁷, the authors also explored whether this mechanism of action accounts for the biological function of endothelial circRNAs, by merging the RNA sequencing data with Argonaute HITS-CLIP data. Here the majority of circRNAs were shown to not possess a microRNA binding site, and only a small number have more than one binding site, suggesting that the majority of circRNAs are not acting as miRNA sponges, although this requires further exploration.

Cardiovascular aging-associated non-coding RNAs

The role of aging associated non-coding RNAs has been recently reviewed ¹⁸. Here we focus on novel lncRNAs that were not covered in the aforementioned review. The hypoxia-sensitive nuclear-localised lncRNA Meg3 was induced highly in endothelial cells of aged mice *in vivo* compared to controls and its levels correlate with aging in human heart tissue ¹⁹. *In vitro*, Meg3 was increased in replicative senescent

HUVECs. Silencing of Meg3 using LNA gapmeRs induced angiogenic sprouting and proliferation and repressed senescence as evidenced by the reduction of SA- β -galactosidase activity of endothelial cells *in vitro*. Conversely, lentiviral overexpression of Meg3 inhibited sprouting angiogenesis and cell cycle progression, although splicing isoforms of Meg3 show differential effects. *In vivo*, silencing of Meg3 in aged mice using gapmeRs in combination with hind limb ischemia significantly repressed Meg3 levels in the hind limb and increased recovery of perfusion compared to control mice. These results demonstrate that silencing Meg3 may be a potential strategy to reduce endothelial senescence and increase regenerative angiogenesis. Of note, Meg3 is also expressed in other non-endothelial cells such as cardiac fibroblasts and its silencing was effective in reducing cardiac fibrosis showing importance of this lncRNA broadly as a potential target in the treatment of cardiovascular diseases ²⁰.

A novel approach for aged patients with cardiovascular diseases using non-coding RNAs as targets was recently presented. [Aging](#) populations show higher incidences of myocardial infarction (MI) and heart failure (HF). With regards to miRNAs, miR-22 was shown to be strongly increased during aging in murine and human hearts and was identified as an abundant and strong inhibitor of cardioprotective autophagy ²¹. Inhibition of miR-22 in aging cardiomyocytes activated autophagy and inhibited cellular hypertrophy. Pharmacological inhibition of miR-22 post-MI in older mice activated cardiac autophagy, prevented post-infarction remodeling, and improved cardiac function compared with control subjects. Interestingly, similar effects were less pronounced in younger mice with significantly lower cardiac miR-22 expression levels. In addition, circulating levels of miR-22 in 154 patients with systolic HF were highly associated with early mortality. Thus, miR-22 seems to be an important regulator of cardiac autophagy and a potential therapeutic target, especially in the

older myocardium. Clearly, targeting therapeutics to the aged or diseased myocardium in human is challenging and requires sophisticated delivery strategies to be developed.

Non-coding RNAs in smooth muscle cell biology

The expression and function of long non-coding RNA in smooth muscle cells remains relatively poorly defined. Aside from SENCER¹⁰, a recent study identified a single transcript (3 exons) lncRNA called SMILR (Smooth Muscle cell Induced LncRNA) that was activated following exposure of basal vSMC to pro-proliferative signals. Following exposure to a combination of platelet-derived growth factor and interleukin-1 α , SMILR was induced²². Interestingly SMILR was localized both in the nuclear and cytoplasmic compartments, suggestive of differential modes of action within the cell. Further, an accurate lncRNA quantification assay for secretion from cells and human plasma samples was developed. Indeed, plasma levels of SMILR were elevated in patients with higher C-reactive protein levels compared to patients with lower levels, albeit in a small population sample set. Using a siRNA approach, an anti-proliferative effect following efficient downregulation of SMILR was identified, with effects on the neighboring gene HAS2. Further, levels of SMILR were higher in patients with advanced atherosclerosis compared to stable patient samples, suggesting relevance of human disease. These studies clearly show the importance of lncRNA expression on function of vSMC. Since vSMC are centrally important in vascular health and disease, this suggests a much greater understanding of both required and essential lncRNA characteristics. Several questions remain regarding the function of SMILR. These include the mode of action with respect to vSMC proliferation. Further, how this is consistent across vascular beds and

vasculoproliferative diseases, as well as refining the therapeutic potential of SMILR inhibition to block proliferation. Notably, in the context of vein graft failure, an anti-proliferative strategy would provide likely efficacy when considering the predominant role of vSMC in vein graft neointima formation. Other studies have also demonstrated the importance of lncRNA in vSMC function ^{23, 24}, consistent with the notion that they hold important regulatory potential in vascular health and disease.

Non-coding RNAs in the control of mitochondrial function and energy metabolism

Recently, miRNAs emerged as central regulators of mitochondrial function and energy metabolism in diabetes, hypertension, ischemia, atherosclerosis and cardiotoxicity. Mitochondrial miRNAs –also mitomiRs- are enriched in those diseases. In diabetes mellitus, mitomiRs are enriched in spatially distinct compartments ²⁵, whereas in hypertensive- hearts their expression differ in the early and later stage of heart failure ²⁶. In general, miR-146a, -181c and -378 act as important therapeutic targets affecting mitochondrial function in cardiovascular diseases. MiR-146a was first reported to affect cardiac metabolism during peripartum cardiomyopathy ²⁷. Uptake by cardiomyocytes of endothelial cell-released miR-146a decreased the metabolic activity of cardiomyocytes during pregnancy, with downregulation of Erbb4, Notch1 and Irak1. Inhibition of miR-146a is thereby protective. *Its* suppression is not only beneficial in peripartum cardiomyopathy, but also in pressure-overload induced cardiomyopathy ²⁸, and in atherosclerosis ²⁹. Inhibition of miR-146a in pressure overload –either with aortic banding or angiotensin-II infusion- blunted the cardiac hypertrophic response and protected against systolic dysfunction ²⁹. MiR-146a decreased dihydrolipoyl succinyl transferase (DLST) levels, a rate-controlling enzyme

CVR-2018-115

in the tricarboxyl acid (TCA) cycle in the failing heart, thereby impairing cardiac oxidative metabolism. Both fatty acid and glucose oxidation decreased upon pressure overload in wild type mice, but were preserved upon miR-146a inhibition. Increase of DLST upon loss of miR-146a helped to preserve these oxidative fluxes, protecting against maladaptive hypertrophy and dysfunction. As in peripartum cardiomyopathy ²⁷ and in atherosclerosis ²⁹, miR-146a seems to be mainly derived from endothelial cells. In line, also in atherosclerosis, deficiency of miR-146a in those endothelial cells tempered the chronic inflammatory response to the atherogenic high fat diet, thereby protecting against atheroma formation ²⁹. MiR-181c is another detrimental mitomiR involved in mitochondrial function. Its inhibition increases Bcl2, a key-player in mitochondrial apoptosis and morphology, and thereby protects against cardiomyocyte apoptosis *in vitro* ³⁰. In doxorubicin-induced toxicity *in vivo*, miR-181c inhibition decreases the reactive oxygen species production and reduces basal mitochondrial respiration ³¹. In ischemic hearts, miR-181c targets mitochondrial COX1, and its deficiency thereby resulted in decreased infarct size, emphasizing the overall cardio-protective effect of miR-181c inhibition. Further, presence of miR-378 attenuated ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes ³² and blunted cardiac hypertrophy and dysfunction upon cardiac overload by targeting Ras signaling ³³. In the diabetic heart, antagomiR blockade of this mitomiR-378 increased ATP6 protein production and thereby also improved cardiac function ²⁵. In a human infarct study, miR-378 modulated the proangiogenic capacity of CD34⁺ progenitor cells after myocardial infarction, with clear stimulatory effects on endothelial cells as confirmed *in vitro* and *in vivo* ³⁴.

In conclusion, diverse mitomiR modulate mitochondrial function in cardiovascular diseases caused by ischemia, the metabolic syndrome –diabetes, hypertension and hyperlipidemia-, and cardiotoxic agents. Whereas inhibition of the mitomiRs-146a is

beneficial in hypertensive and peripartum cardiomyopathy, and in atherosclerotic disease, and inhibition of miR-181c in ischemic and toxic cardiomyopathy, the presence of miR-378 is needed to protect against cardiac dysfunction caused by ischemic injury and maladaptive hypertrophy.

Circulating microRNAs as novel cardiovascular biomarkers

Previous studies have highlighted the presence of endogenous circulating miRNAs that are not cell-associated. Zampetaki and colleagues have performed the first systematic analysis of circulating miRNAs in a large community-based study and revealed a diagnostic potential of miRNA changes associated with type 2 diabetes and cardiovascular disease ^{35, 36}. In subsequent studies, it has become apparent that platelets have abundant amounts of miRNAs ³⁷, and that circulating miRNAs reflect platelet activation ^{38, 39}. As platelets are anucleate and do not perform transcription, it was initially thought that circulating miRNAs are unlikely to be platelet-derived. However, surprisingly many abundant plasma and serum miRNAs, including miRNAs like miR-126 that were previously thought to be endothelial specific, can originate from platelets ³⁷⁻³⁹. YRNAs is another species of circulating non-coding RNAs that is platelet-derived ³⁹. There still remains a gap in our understanding of how changes in platelet biology relate to circulating miRNAs. In contrast, miR-122 is a liver-specific miRNA that is readily detectable in the circulation ⁴⁰. Notably, circulating levels of miR-122 are strongly associated with the risk of developing metabolic syndrome ⁴¹. The presence of circulating tissue-derived miRNAs provides the possibility of a cross-organ communication by miRNAs.

Conclusion and Outlook

The discovery of miRNAs and other non-coding RNAs such as lncRNAs and circRNAs that are involved in transcriptional and other functional regulation of the vasculature have transformed our understanding of biological processes and disease development especially in cardiovascular diseases. This might lead to new therapeutics and diagnostics. The non-coding RNAome offers promising opportunities for treating and assessing cardiovascular disease, but many obstacles still need to be overcome. A major point to address in therapeutic use of non-coding RNAs is to develop tailored drug delivery with e.g. heart specificity. Next to that, lncRNA and circRNAs are relatively new areas of research, thus it is paramount to better understand their biological function.

Acknowledgement

This study was supported by grants from the German Ministry for Education and Research (IFB-Tx to T.T., 01EO1302) and the Leducq Fondation (MIRVAD). AHB is supported by the British Heart Foundation Chair of Translational Cardiovascular Sciences and a European Research Council Advanced grant (VASC MIR). Prof. M. Mayr is a British Heart Foundation (BHF) Chair Holder (CH/16/3/32406) with BHF programme grant support (RG/16/14/32397), support by the National Institute of Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London in partnership with King's College Hospital, and an excellent initiative (Competence Centers for Excellent Technologies [COMET]) of the FFG (Austrian Research Promotion Agency): Research Center of Excellence in Vascular Ageing-Tyrol, VASCage (K- Project Nr. 843536) funded by BMVIT (Federal Ministry for Transport, Innovation and

CVR-2018-115

Technology), BMWFW (federal Ministry of Science, Research and Economy), the Wirtschaftsagentur Wien, and Standortagentur Tirol.

Disclosures

TT filed and licensed patents about non-coding RNAs. TT holds shares of Cardior Pharmaceuticals GmbH. AHB filed a patent on the lncRNA SMILR. MM filed and licensed patents on miRNAs as cardiovascular biomarkers.

References

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;**385**:117-171.
2. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. *Physiol Rev* 2016;**96**:1297-1325.
3. Fiedler J, Breckwoldt K, Remmele CW, Hartmann D, Dittrich M, Pfanne A, Just A, Xiao K, Kunz M, Muller T, Hansen A, Geffers R, Dandekar T, Eschenhagen T, Thum T. Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization. *J Am Coll Cardiol* 2015;**66**:2005-2015.
4. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, Loyer X, Soutschek J, Brand T, Tuschl T, Heineke J, Martin U, Schulte-Merker S, Ertl G, Engelhardt S, Bauersachs J, Thum T. MicroRNA-24 regulates vascularity after myocardial infarction. *Circulation* 2011;**124**:720-730.
5. Thum T, Haverich A, Borlak J. Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology. *Faseb j* 2000;**14**:740-751.
6. Hartmann D, Fiedler J, Sonnenschein K, Just A, Pfanne A, Zimmer K, Remke J, Foinquinos A, Butzlaff M, Schimmel K, Maegdefessel L, Hilfiker-Kleiner D, Lachmann N, Schober A, Froese N, Heineke J, Bauersachs J, Batkai S, Thum T. MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. *Circulation* 2016;**134**:1973-1990.
7. Neumann P, Jae N, Knau A, Glaser SF, Fouani Y, Rossbach O, Kruger M, John D, Bindereif A, Grote P, Boon RA, Dimmeler S. The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2. *Nat Commun* 2018;**9**:237-017-02431-1.
8. Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Korniyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, Lopez B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschope C, Chang CP. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. *Nat Commun* 2016;**7**:13710.
9. Boulberdaa M, Scott E, Ballantyne M, Garcia R, Descamps B, Angelini GD, Brittan M, Hunter A, McBride M, McClure J, Miano JM, Emanuelli C, Mills NL, Mountford JC, Baker AH. A Role for the Long Noncoding RNA SENCR in Commitment and Function of Endothelial Cells. *Mol Ther* 2016;**24**:978-990.
10. Bell RD, Long X, Lin M, Bergmann JH, Nanda V, Cowan SL, Zhou Q, Han Y, Spector DL, Zheng D, Miano JM. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. *Arterioscler Thromb Vasc Biol* 2014;**34**:1249-1259.
11. Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. *Circ Res* 2014;**114**:1389-1397.
12. Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. *Circ Res* 2015;**116**:737-750.

13. Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, Tao ZF, Song YC, Chen Q, Jiang Q. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. *Circ Res* 2015;**116**:1143-1156.
14. de Gonzalo-Calvo D, Kenneweg F, Bang C, Toro R, van der Meer RW, Rijzewijk LJ, Smit JW, Lamb HJ, Llorente-Cortes V, Thum T. Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. *Sci Rep* 2016;**6**:37354.
15. Gupta SK, Garg A, Bar C, Chatterjee S, Foinquinos A, Milting H, Streckfuss-Bomeke K, Fiedler J, Thum T. Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression. *Circ Res* 2017;.
16. Boeckel JN, Jae N, Heumuller AW, Chen W, Boon RA, Stellos K, Zeiher AM, John D, Uchida S, Dimmeler S. Identification and Characterization of Hypoxia-Regulated Endothelial Circular RNA. *Circ Res* 2015;**117**:884-890.
17. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 2013;**495**:333-338.
18. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, Dorn GW, 2nd, Thum T, Heymans S. Cardiolinc network. Long noncoding RNAs in cardiac development and ageing. *Nat Rev Cardiol* 2015;**12**:415-425.
19. Boon RA, Hofmann P, Michalik KM, Lozano-Vidal N, Berghauer D, Fischer A, Knau A, Jae N, Schurmann C, Dimmeler S. Long Noncoding RNA Meg3 Controls Endothelial Cell Aging and Function: Implications for Regenerative Angiogenesis. *J Am Coll Cardiol* 2016;**68**:2589-2591.
20. Piccoli MT, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL, Garg A, Remke J, Zimmer K, Batkai S, Thum T. Inhibition of the Cardiac Fibroblast-Enriched lncRNA Meg3 Prevents Cardiac Fibrosis and Diastolic Dysfunction. *Circ Res* 2017;**121**:575-583.
21. Gupta SK, Foinquinos A, Thum S, Remke J, Zimmer K, Bauters C, de Groote P, Boon RA, de Windt LJ, Preissl S, Hein L, Batkai S, Pinet F, Thum T. Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. *J Am Coll Cardiol* 2016;**68**:1557-1571.
22. Ballantyne MD, Pinel K, Dakin R, Vesey AT, Diver L, Mackenzie R, Garcia R, Welsh P, Sattar N, Hamilton G, Joshi N, Dweck MR, Miano JM, McBride MW, Newby DE, McDonald RA, Baker AH. Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation. *Circulation* 2016;**133**:2050-2065.
23. Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, Cai Y, Huang H, Yang Y, Liu Y, Xu Z, He D, Zhang X, Hu X, Pinello L, Zhong D, He F, Yuan GC, Wang DZ, Zeng C. lincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. *Circulation* 2014;**130**:1452-1465.
24. Leung A, Trac C, Jin W, Lanting L, Akbany A, Saetrom P, Schones DE, Natarajan R. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. *Circ Res* 2013;**113**:266-278.
25. Jagannathan R, Thapa D, Nichols CE, Shepherd DL, Stricker JC, Croston TL, Baseler WA, Lewis SE, Martinez I, Hollander JM. Translational Regulation of the Mitochondrial Genome Following Redistribution of Mitochondrial MicroRNA in the Diabetic Heart. *Circ Cardiovasc Genet* 2015;**8**:785-802.
26. Wang X, Song C, Zhou X, Han X, Li J, Wang Z, Shang H, Liu Y, Cao H. Mitochondria Associated MicroRNA Expression Profiling of Heart Failure. *Biomed Res Int* 2017;**2017**:4042509.

27. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D, Struman I. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. *J Clin Invest* 2013;**123**:2143-2154.
28. Heggermont WA, Papageorgiou AP, Quaegebeur A, Deckx S, Carai P, Verhesen W, Eelen G, Schoors S, van Leeuwen R, Alekseev S, Elzenaar I, Vinckier S, Pokreisz P, Walravens AS, Gijssbers R, Van Den Haute C, Nickel A, Schroen B, van Bilsen M, Janssens S, Maack C, Pinto Y, Carmeliet P, Heymans S. Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction. *Circulation* 2017;**136**:747-761.
29. Cheng HS, Besla R, Li A, Chen Z, Shikatani EA, Nazari-Jahantigh M, Hammoutene A, Nguyen MA, Geoffrion M, Cai L, Khyzha N, Li T, MacParland SA, Husain M, Cybulsky MI, Boulanger CM, Temel RE, Schober A, Rayner KJ, Robbins CS, Fish JE. Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a. *Circ Res* 2017;**121**:354-367.
30. Wang H, Li J, Chi H, Zhang F, Zhu X, Cai J, Yang X. MicroRNA-181c targets Bcl-2 and regulates mitochondrial morphology in myocardial cells. *J Cell Mol Med* 2015;**19**:2084-2097.
31. Das S, Kohr M, Dunkerly-Eyring B, Lee DI, Bedja D, Kent OA, Leung AK, Henao-Mejia J, Flavell RA, Steenbergen C. Divergent Effects of miR-181 Family Members on Myocardial Function Through Protective Cytosolic and Detrimental Mitochondrial microRNA Targets. *J Am Heart Assoc* 2017;**6**:10.1161/JAHA.116.004694.
32. Fang J, Song XW, Tian J, Chen HY, Li DF, Wang JF, Ren AJ, Yuan WJ, Lin L. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. *Apoptosis* 2012;**17**:410-423.
33. Nagalingam RS, Sundaresan NR, Gupta MP, Geenen DL, Solaro RJ, Gupta M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. *J Biol Chem* 2013;**288**:11216-11232.
34. Templin C, Volkmann J, Emmert MY, Mocharla P, Muller M, Kraenkel N, Ghadri JR, Meyer M, Styp-Rekowska B, Briand S, Klingenberg R, Jaguszewski M, Matter CM, Djonov V, Mach F, Windecker S, Hoerstrup SP, Thum T, Luscher TF, Landmesser U. Increased Proangiogenic Activity of Mobilized CD34+ Progenitor Cells of Patients With Acute ST-Segment-Elevation Myocardial Infarction: Role of Differential MicroRNA-378 Expression. *Arterioscler Thromb Vasc Biol* 2017;**37**:341-349.
35. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res* 2010;**107**:810-817.
36. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating MicroRNAs and risk of myocardial infarction. *J Am Coll Cardiol* 2012;**60**:290-299.
37. Sunderland N, Skroblin P, Barwari T, Huntley RP, Lu R, Joshi A, Lovering RC, Mayr M. MicroRNA Biomarkers and Platelet Reactivity: The Clot Thickens. *Circ Res* 2017;**120**:418-435.
38. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, Crosby-Nwaobi R, Prokopi M, Drozdov I, Langley SR, Sivaprasad S, Markus HS, Mitchell JA, Warner TD, Kiechl S, Mayr M. Circulating microRNAs as novel biomarkers for platelet activation. *Circ Res* 2013;**112**:595-600.

39. Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, Sunderland NP, Willeit K, Morton AC, Armstrong PC, Chan MV, Lu R, Yin X, Gracio F, Dudek K, Langley SR, Zampetaki A, de Rinaldis E, Ye S, Warner TD, Saxena A, Kiechl S, Storey RF, Mayr M. Association of MicroRNAs and YRNAs With Platelet Function. *Circ Res* 2016;**118**:420-432.
40. Willeit P, Skroblin P, Kiechl S, Fernandez-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? *Eur Heart J* 2016;**37**:3260-3266.
41. Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramirez CM, Goedeke L, Rotllan N, Bonora E, Hughes AD, Santer P, Fernandez-Hernando C, Tilg H, Willeit J, Kiechl S, Mayr M. Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. *Diabetes* 2017;**66**:347-357.

Figure Legends

Figure 1. Non-coding RNAs as angiogenic therapeutic entry points.

Enhancement or inhibition strategy can be followed for modulation of vascular non-coding RNAs. Circular RNA, miRNA or long non-coding RNA are target structures for therapeutic intervention. Modulation of RNA subtypes triggers expression changes (up or down) of interacting effectors (e.g. proteins such as chromatin modifiers or ribosomal factors or different RNA species). Collectively cardiac vascularization is positively or negatively influenced dependent on the chosen non-coding RNA therapy.

Figure 2. GATA2 as a central player for angiogenic non-coding RNAs (modified from ⁶).

Besides the regulation of GATA2-dependent coding genes (e.g. ICAM1, VCAM1), endothelial transcription factor GATA2 directly controls transcription of miR-126 / miR-221 locus. Interestingly loss of GATA2 causes DNA hypomethylation thereby activating miR-221 expression. Next to that, GATA2 repression lowers miR-126 expression levels causing an upregulation of anti-angiogenic factors. Overall, downstream modulation leads to anti-angiogenic outcome and imbalanced endothelial cell biology.

Table 1. Non-coding RNA associated biomarker studies

Non-coding RNA	Disease association	Study reference
miR-126	type 2 diabetes	35
miR-126, miR-197, miR-223	myocardial infarction	36
miR-126, miR-150, miR-191, miR-223	atherosclerosis	38
YRNA	platelet reactivity	39
miR-122	Metabolic syndrome development and type 2 diabetes	41




Figure 2

Figure 2: GATA2 as a central player for angiogenic non-coding RNAs modified from Hartmann, Fiedler et al., 2016

